Skip to main navigation
Close
Menu
Main navigation
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2025
GRx+Biosims 2024
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action
Breadcrumb
Association for Accessible Medicines
Resources
Resources
Share
Find up-to-date information on generics and biosimilars
Filter Resources
Issues
Biosimilar User Fee Act (BsUFA)
Biosimilars
Complex Generics
Drug Approval Process (GDUFA)
Drug Prices
Drug Shortages
Generic Drug Labeling
Generic Supply Chain
IP Issues
Low Income Subsidies (LIS in Part D)
Medicaid
Medicare
NAFTA
Patent Reform
Patient Stories
Pharmaceutical Waste Take Back
Preventing Drug Abuse
Quality
REMS/Sample Acquisition Remedies
State Initiatives
Tariffs
Trade
Transparency
User Fees
Resource Type
Blog
Amicus Brief
Press Release
Infographic
Video
Report
Fact Sheet
Presentation
Press Release
Feb 15, 2023
| Susan Reilly
AAM Statement on CMMI Report
Press Release
Feb 15, 2023
| Susan Reilly
New Social Media Campaign Unveiled to Raise Awareness of the Essential Role of Generic Medicine in Americans’ Lives
Video
Feb 14, 2023
| Erica Klinger
A Fireside Chat with AAM Chair, Christine Baeder and Mark Cuban, Entrepreneur and Cost Plus founder.
Press Release
Feb 13, 2023
| Susan Reilly
Christine Baeder Named Chair of the Association for Accessible Medicines Board of Directors
Blog
Feb 9, 2023
| Jonathan Kimball
The Quickest Route to U.S. Essential Medicines Production: Existing and Idle Production Sites
Press Release
Jan 30, 2023
| Susan Reilly
AAM Applauds CMS for Requiring Health Plans to Place Generic Drugs On Generic Tiers
Fact Sheet
Jan 26, 2023
| Erica Klinger
AAM Opposes HF17 and SF168 Which Won’t Bring Down Drug Prices for Minnesota Patients
Press Release
Jan 23, 2023
| Susan Reilly
Study Finds Middlemen Increasingly Block Patient Access to New Generics
Blog
Jan 5, 2023
| Erica Klinger
Desi is Back Playing Soccer and Doing "Normal Kid" Stuff
Blog
Jan 3, 2023
| Sara Skubikowski
Generics and Biosimilars Offer Savings for Patients Fighting Cancer, Heart Disease and Other Conditions
Blog
Dec 21, 2022
| Craig Burton
Ensuring Patient Access to Amoxicillin When Demand is High
Press Release
Dec 20, 2022
| Susan Reilly
AAM Statement on the Consolidated Appropriations Act of 2023
Load More
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2025
GRx+Biosims 2024
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action